Health
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- BOSTON, March 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare n
About this update from Rhythm Pharmaceuticals, Inc.
[{"type":"image","alt":"Rhythm Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Rhythm Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/6c26dd8fa407cbf7aa92759a8a5fb54c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AurFDXSTd0Q12WnAaUwFIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6c26dd8fa407cbf7aa92759a8a5fb54c","width":300,"height":105}},"lazy":false},{"type":"text","content":"-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- ","length":198,"tagName":"p"},{"type":"text","content":"-- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity --","length":106,"tagName":"p"},{"type":"text","content":"BOSTON, March 01, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced additional positive data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity (HO). This new data set includes 12 patients from a Japanese cohort and 10 supplemental patients who were enrolled in addition to the primary 120-patient pivotal cohort.","length":542,"tagName":"p"},{"type":"text","content":"Highlights from these 52-week data include:","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"-18.8% placebo-adjusted difference1 in BMI reduction (N=142);","length":61,"tagName":"p"}]},{"val":[{"type":"text","content":"Primary endpoint of mean BMI reduction of -16.4% from baseline for all patients on setmelanotide therapy (n=94) compared with +2.4% BMI change for patients on placebo (n=48) at 52 weeks (95% CI; p<0.0001); and","length":212,"tagName":"p"}]},{"val":[{"type":"text","content":"Among patients aged 12 and older (n=98), the setmelanotide group (n=66) showed an average weekly reduction of 2.5 points in the weekly average most hunger score, compared with a 1.3‑point reduction in the placebo group (n=32) (p=0.0015). ","length":237,"tagName":"p"}]}],"t...